parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in erythrocyte progenitors	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 14168

SLC43A3 in microglia, braak+0.46 (p 0.212) → -0.28 (p 0.472)receipt 14176
SLC43A3 in dopamine neurons, braak-0.61 (p 0.078) → -0.01 (p 0.982)receipt 14177

receipt 14177: SLC43A3 in dopamine neurons, braak

power: full sample -0.45 (p 0.059, n 18), 95% CI -0.76 to +0.02. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.49 (p 0.037, n 18). holds up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.55 (p 0.017, n 18). not the mix.
skeptic: leave-one-out range -0.57 to -0.38, sign flips 0; without severely affected donors -0.45 (p 0.059, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SLC43A3 in dopamine neurons.

case closed: nothing better to follow up.

receipt 14176: SLC43A3 in microglia, braak

power: full sample +0.09 (p 0.722, n 18), 95% CI -0.39 to +0.53. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.09 (p 0.722, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.21 (p 0.408, n 18). could be the mix.
skeptic: leave-one-out range -0.01 to +0.25, sign flips 1; without severely affected donors +0.09 (p 0.722, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SLC43A3 in microglia.

case closed: nothing better to follow up.

loading the receipts